Sirtris Pharmaceuticals and two leading sirtuin researchers, David A Sinclair, Ph.D. and Leonard P. Guarente, Ph.D., have published a review of the work being done to develop therapies to treat diseases associated with aging. The review centers on the discovery of sirtuins and their role in the aging process. Additionally, the article discusses the drug development path of SIRT1 activators as potential treatments for a range of diseases of aging including metabolic disorders such as Type 2 Diabetes, mitochondrial disorders such as MELAS, neurological disorders, and cancer.
"This review summarizes the growing body of evidence regarding the substantial therapeutic potential of SIRT1 activators, such as SRT501, our proprietary formulation of resveratrol, and new chemical entities which are 1000 times more potent than resveratrol, to address a broad range of diseases of aging," said Christoph Westphal, M.D., Ph.D., CEO of Sirtris. David A. Sinclair, Ph.D. is a scientific co-founder, member of the board of directors of Sirtris Pharmaceuticals, associate professor of pathology at Harvard Medical School, and director of the Glenn Laboratories for the Biological Mechanisms of Aging. Leonard P. Guarente is the Novartis Professor of Biology at the Massachusetts Institute of Technology. Sirtris was a 2007 Fierce 15 company.
- here's the link to their report